Saturday, May 15, 2021

CureVac and Novavax vaccines against Covid-19 will begin Phase 3 in Mexico

Must read

Likewise, the Chinese company CanSino will announce the findings of its phase 3, which began in October.

Entrepreneur’s New Year’s Guide

Let the business resources in our guide inspire you and help you achieve your goals in 2021.


3 min read

This article was translated from our Spanish edition using AI technologies. Errors may exist due to this process.


This story originally appeared on Alto Nivel

The Secretary of Foreign Affairs, Marcelo Ebrard , shared on his Twitter account that the CUREVAC (German) and Novavax (USA ) vaccines would start phase 3 in Mexico and that the necessary doses for this will arrive next week.

He also added that the Chinese CanSino vaccine, which has 15,000 volunteers in Mexico , is about to present the findings of its phase 3, which began in October.

In the case of the German company, it will start in Monterrey, in alliance with TecSalud, for this it will look for between 2,000 and 3,000 Mexican volunteers, its estimated starting date will be from the last week of January, according to the doctor Michelle Martínez, who is head of the Epidemiological Surveillance Unit of TecSalud and leader of the Covid-19 Program.

On the other hand, Novavax will look for volunteers who are in the demographic groups that have been most affected by the SARS-CoV-2 virus, as well as older adults or those with comorbidities.

To learn more: Cofepris approved phase 3 of the German CureVac vaccine in Mexico

What is known about the CUREVAC vaccine?

The German CUREVAC vaccine is composed of two doses, in addition to using the same technology as that of Pfizer / BioNTech and Moderna , the messenger RNA.

CureVac plans to launch the anticovid vaccine this year, it can remain stored for three months at refrigerator temperature, unlike Pfizer that requires -70 degrees and Modern at -20.

About the Novavax vaccine:

Novavax is an American company that develops vaccines, it is applied in two doses, 21 days apart. He demonstrated a robust response in phase 1 and 2, which generates highly neutralizing antibodies against the virus.

“Our vaccine technology combines the power and speed of genetic engineering with the immunogenicity enhancing properties of our Matrix-M adjuvant to efficiently produce highly immunogenic particles targeting some of the most urgent viral infectious diseases.” according to the information on the Novavax page.

In case you are interested: What are the differences between the three main COVID-19 vaccines?

Source link

More articles

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Latest article